Details for New Drug Application (NDA): 214835
✉ Email this page to a colleague
The generic ingredient in RISVAN is risperidone. There are thirty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.
Summary for 214835
Tradename: | RISVAN |
Applicant: | Labs Farms Rovi Sa |
Ingredient: | risperidone |
Patents: | 14 |
Suppliers and Packaging for NDA: 214835
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835 | NDA | Laboratorios Farmaceuticos Rovi, S.A. | 82090-001 | 82090-001-01 | 1 KIT in 1 CARTON (82090-001-01) / 1 POUCH in 1 KIT / 2 SYRINGE in 1 POUCH / 575 mg in 1 SYRINGE |
RISVAN | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 214835 | NDA | Laboratorios Farmaceuticos Rovi, S.A. | 82090-003 | 82090-003-01 | 1 KIT in 1 CARTON (82090-003-01) / 1 POUCH in 1 KIT / 2 SYRINGE in 1 POUCH / 766.7 mg in 1 SYRINGE |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Strength | 75MG | ||||
Approval Date: | Mar 29, 2024 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | Mar 29, 2027 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | ⤷ Subscribe | Patent Expiration: | May 31, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Subscribe | Patent Expiration: | May 31, 2031 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription